Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)

Summary

This is a Phase 2, open-label, dose-rising study evaluating the safety, tolerability, and preliminary efficacy of three concentrations of SOR007 ointment (0.15%, 1.0%, and 2.0%) applied topically once per week for four weeks to the ectocervix of subjects with high grade cervical intraepithelial neoplasia (CIN).

Timeline

Start

2017-10-01

Primary completion

2018-12-01

Completion

2019-03-01

Outcome

Outcome not reported

Stopped: “Study never initiated”

Drugs

Indications